Enabling API connection with healthcare providers telemedicine platforms and enhancing overall user’s experience
SAN DIEGO, Jan. 04, 2022 (GLOBE NEWSWIRE) — GBT Technologies Inc. (OTC PINK: GTCH) (“GBT”, or the “Company”) is now developing a mobile application for its AI empowered healthcare advisory system.
The mobile application will be working with a back-end infrastructure, enabling an efficient and user-friendly interface. The mobile application will support private accounts, with a question & answer conversation type advising system, and in future versions, natural voice support using NLP (Natural Language Processing) technology. The mobile technology will be synchronized with the system’s web application for easier and intuitive user interactions. The AI health advisory system will be trained with health-related information and connected with accredited data sources, among them are the CDC (Centers for Disease Control and Prevention), NCBI (National Center for Biotechnology Information), medical text books, and other credible resources. The system is aimed to perform as a general health Q/A advisory system, providing first-line of medical advice.
GBT plans to further develop the system to include intelligent telemedicine capabilities that will assist patients and healthcare specialists through connected devices. The AI-driven computer program will be able to connect to healthcare providers computerized systems through an API (Application Programming Interface); effectively, establishing direct telemedicine communications. The mobile technology plans to incorporate GBT’s qTerm vital device to enable real-time vital information sharing with a healthcare professional during telemedicine sessions. The mobile application will support iOS and Android platforms and is targeted to be complete during the Q2 of 2022.
“As a natural evolution of our AI-driven health advisory system, we are now developing its mobile application to work with full synchronization together its web interface. As with the system’s web application, the mobile app will provide a conversational interface type, designed to be at the forefront of an AI program that processes the user’s data. The knowledge base health advisory system will be connected to credible health-related data resources, among them are the CDC, medical text books and NCBI, to provide credible advice for general health related questions. Additionally, we plan to implement all the necessary infrastructure within the mobile application to establish future telemedicine capabilities with clinics and healthcare providers through an API interface. The mobile app architecture will include qTerm’s vital device support to enable future real-time vital data sharing within telemedicine sessions. The healthcare advisory agent is aimed to provide first line health related advice and become an assistance tool for healthcare professionals. One of its major advantages is the capability to provide healthcare support for remote locations. The mobile application design is focusing on a secured communication protocol, efficient data management and user-friendly interface. The mobile app will support iOS and Android platforms, providing intelligent healthcare assistance, monitoring and telemedicine capabilities for our new healthcare era,” said Danny Rittman, the Company’s CTO.
There is no guarantee that the Company will be successful in researching, developing or implementing this system. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched and developed, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps.
GBT Technologies, Inc. (OTC PINK: GTCH) (“GBT”) (http://gbtti.com) is a development stage company which considers itself a native of Internet of Things (IoT), Artificial Intelligence (AI) and Enabled Mobile Technology Platforms used to increase IC performance. GBT has assembled a team with extensive technology expertise and is building an intellectual property portfolio consisting of many patents. GBT’s mission, to license the technology and IP to synergetic partners in the areas of hardware and software. Once commercialized, it is GBT’s goal to have a suite of products including smart microchips, AI, encryption, Blockchain, IC design, mobile security applications, database management protocols, with tracking and supporting cloud software (without the need for GPS). GBT envisions this system as a creation of a global mesh network using advanced nodes and super performing new generation IC technology. The core of the system will be its advanced microchip technology; technology that can be installed in any mobile or fixed device worldwide. GBT’s vision is to produce this system as a low cost, secure, private-mesh-network between any and all enabled devices. Thus, providing shared processing, advanced mobile database management and sharing while using these enhanced mobile features as an alternative to traditional carrier services.
Certain statements contained in this press release may constitute “forward-looking statements”. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, governmental and public policy changes, the Company’s ability to raise capital on acceptable terms, if at all, the Company’s successful development of its products and the integration into its existing products and the commercial acceptance of the Company’s products. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of the press release.